| 1. |
- Åkesson, Torsten, et al.
(författare)
-
Status of design and construction of the Transition Radiation Tracker (TRT) for the ATLAS experiment at the LHC
- 2004
-
Ingår i: Nuclear Instruments & Methods in Physics Research. Section A: Accelerators, Spectrometers, Detectors, and Associated Equipment. - : Elsevier BV. - 0167-5087 .- 0168-9002. ; 522:1-2, s. 131-145
-
Tidskriftsartikel (refereegranskat)abstract
- The ATLAS Inner Detector consists of three sub-systems, the Pixel Detector at the innermost radius, the Semi-Conductor Tracker at intermediate radii, and the Transition Radiation Tracker (TRT) at the outermost radius in front of the electromagnetic calorimeter. The TRT provides a combination of continuous tracking with many projective measurements based on individual drift-tubes (or straws) and of electron identification based on radiator fibres or foils interleaved between the straws themselves. This paper describes the current status of design and construction of the various components of the TRT: the assembly of the barrel modules has recently been completed, that of the end-cap wheels is well underway, and the on-detector front-end electronics is in production. The detector modules and front-end electronics boards will be integrated together over the next year, the barrel and end-cap TRT parts will be assembled and tested with their SCT counterparts during 2005 and installation and commissioning in the ATLAS pit will take place at the end of 2005 and the beginning of 2006. (C) 2004 Elsevier B.V. All rights reserved.
|
|
| 2. |
- Åkesson, Torsten, et al.
(författare)
-
ATLAS Transition Radiation Tracker test-beam results
- 2004
-
Ingår i: Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. - : Elsevier BV. - 0168-9002. ; 522:1-2, s. 50-55
-
Konferensbidrag (refereegranskat)abstract
- Several prototypes of the Transition Radiation Tracker for the ATLAS experiment at the LHC have been built and tested at the CERN SPS accelerator. Results from detailed studies of the straw-tube hit registration efficiency and drift-time measurements and of the pion and electron spectra without and with radiators are presented.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Åkesson, Torsten, et al.
(författare)
-
Operation of the ATLAS Transition Radiation Tracker under very high irradiation at the CERN LHC
- 2004
-
Ingår i: Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. - : Elsevier BV. - 0168-9002. ; 522:1-2, s. 25-32
-
Konferensbidrag (refereegranskat)abstract
- The ATLAS Transition Radiation Tracker (TRT) performance depends critically on the choice of the active gas and on its properties. The most important operational aspects, which have led to the final choice of the active gas for the operation of the TRT at the LHC design luminosity, are presented. The TRT performance expected at these conditions is reviewed, including pile-up effects at high luminosity. (C) 2004 Elsevier B.V. All rights reserved.
|
|
| 6. |
|
|
| 7. |
- Batista, N, et al.
(författare)
-
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
- 2004
-
Ingår i: Br J Cancer. - 0007-0920. ; 90:9, s. 1740-6
-
Tidskriftsartikel (refereegranskat)abstract
- The addition of oral capecitabine to docetaxel improves response rate, time to progression (TTP) and overall survival in anthracycline-pretreated metastatic breast cancer (MBC). This phase II study evaluates the efficacy and safety of a 21-day cycle of oral capecitabine (1000 mg m(-2) twice daily, days 1-14) plus i.v. paclitaxel (175 mg m(-2), day 1) in anthracycline-pretreated advanced/MBC. In all, 73 patients were enrolled at 13 Swedish and Spanish centres. The objective response rate was 52% (95% confidence interval (CI): 40-63%) in the intent-to-treat population, including complete responses in 11%. Disease was stabilised in a further 29%. The median time to disease progression (TTP) was 8.1 months and the median overall survival was 16.5 months. The combination was generally well tolerated with a predictable safety profile. The most common treatment-related nonhaematological adverse events were hand-foot syndrome (42%), alopecia (30%) and diarrhoea (26%). The only treatment-related Grade 3/4 adverse events occurring in >5% of patients were alopecia (22%) and hand-foot syndrome (11%). Grade 3/4 neutropenia and lymphocytopenia were reported in 12 and 14% of patients, respectively. Capecitabine plus paclitaxel is highly active with a favourable safety profile in anthracycline-pretreated MBC.
|
|
| 8. |
|
|
| 9. |
|
|
